+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate

Jul 15, 2020, 10:53 IST
PTI
Representative image. BCCL
  • In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.
  • The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine."
  • Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.

Advertisement
Drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.

The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that "the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine."

Earlier this month, Zydus had received approval from domestic authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.

It got approval a few days after India's first indigenous COVID-19 vaccine candidate COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 356.50 apiece on BSE, up 0.81 per cent against their previous close.

Advertisement

SEE ALSO:
INTERVIEW: Shaaz Jung opens up about the blood, sweat and years behind the viral images of a rare black panther
Intel will speed up Mukesh Ambani’s 5G run, power him with AI and possibly a Jio laptop⁠— all in return for massive amount of data
Next Article